CytomX Therapeutics CTMX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's accrued liabilities, current?
- CytomX Therapeutics (CTMX) reported accrued liabilities, current of $11.92M in Q1 2026.
- How has CytomX Therapeutics's accrued liabilities, current changed year-over-year?
- CytomX Therapeutics's accrued liabilities, current increased by 4.5% year-over-year, from $11.41M to $11.92M.
- What is the long-term trend for CytomX Therapeutics's accrued liabilities, current?
- Over 5 years (2020 to 2025), CytomX Therapeutics's accrued liabilities, current has grown at a -9.2% compound annual growth rate (CAGR), from $23.06M to $14.2M.